---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-205010"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:22:22.223439+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Viridian Q1 net loss $104.9M; veligrotug PDUFA June 30, elegrobart positive data, BLA Q1 2027

## Summary
- Cash $762.2M at March 31, 2026, down from $874.7M at Dec 31, 2025; net loss $104.9M vs $86.9M YoY.
- Veligrotug BLA under Priority Review with PDUFA target June 30, 2026; launch-ready with hired field teams.
- Elegrobart (subcutaneous) met primary endpoints in REVEAL-1 (active TED) and REVEAL-2 (chronic TED); proptosis responder rates 50-63% vs 15-18% placebo.
- BLA for elegrobart expected Q1 2027; MAA for veligrotug submitted to EMA and accepted for review.
- SG&A jumped to $38.7M from $17.1M due to commercial prep; R&D flat at $77.6M.

## SEC filing metadata
- accession: 0001193125-26-205010
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312526205010/0001193125-26-205010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312526205010/d149508d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-205010
- JSON: https://secwatch.observer/filing/0001193125-26-205010.json
- Plain text: https://secwatch.observer/filing/0001193125-26-205010.txt

## Source-grounded claims
- claim_id: 8e8280d0456dc22bfadcb411621e1cd853146d04
  claim: Viridian Therapeutics, Inc.\DE reported financial results for first quarter ended March 31, 2026.
  evidence_excerpt: On May 5, 2026, Viridian Therapeutics, Inc. issued a press release reporting financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312526205010/0001193125-26-205010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.